Teva Unit Targets Celgene Breast Cancer Drug In IP Suit

Law360, New York (December 15, 2011, 2:03 PM EST) -- Teva Pharmaceutical Industries Ltd. unit Cephalon Inc. on Wednesday hit Celgene Corp. with a lawsuit claiming Celgene's breast cancer treatment Abraxane infringes a patent covering formulations of paclitaxel, the drug’s active ingredient.

Cephalon and specialty pharmaceutical company Acusphere Inc. filed the lawsuit in Massachusetts federal court against Celgene and its subsidiaries Abraxis Bioscience Inc. and Abraxis Bioscience LLC.

The patent-in-suit is assigned to Acusphere and exclusively licensed to Cephalon. Abraxis Bioscience Inc. holds an approved new drug application for Abraxane, which is a pharmaceutical formulation of...
To view the full article, register now.